Amgen, Cytokinetics Heart-Failure Study Hits Main Endpoint, Misses Secondary
October 08 2020 - 9:24AM
Dow Jones News
By Colin Kellaher
Amgen Inc., Cytokinetics Inc. and Laboratoires Servier SA on
Thursday said a pivotal phase 3 study of omecamtiv mecarbil in
patients with heart failure met its primary composite endpoint but
missed its secondary endpoint.
The companies said treatment with omecamtiv mecarbil showed a
statistically significant effect to reduce cardiovascular death or
heart failure events compared to placebo in patients with heart
failure with reduced ejection fraction.
However, the companies said no reduction in the secondary
endpoint of cardiovascular death was observed, adding that adverse
events, including major ischemic cardiac events, were balanced
between treatment arms. Further analyses of the study data are
underway, the companies said.
Amgen, a Thousand Oaks, Calif., biotechnology company, in 2006
formed a collaboration with South San Francisco, Calif.,
biopharmaceutical company Cytokinetics to discover, develop and
commercialize potential treatments for heart failure. The companies
are developing omecamtiv mecarbil with funding and strategic
support from French drug company Servier.
Shares of Cytokinetics, which closed Wednesday at $27.66, were
down more than 37% in premarket trading Thursday. Amgen shares
slipped 3.4% premarket.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 08, 2020 09:09 ET (13:09 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Sep 2023 to Sep 2024